PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
86.64%
Revenue growth exceeding 1.5x VET's 40.03%. David Dodd would verify if faster growth reflects superior business model.
6.97%
Cost increase while VET reduces costs. John Neff would investigate competitive disadvantage.
224.24%
Gross profit growth exceeding 1.5x VET's 73.96%. David Dodd would verify competitive advantages.
73.72%
Margin expansion exceeding 1.5x VET's 24.23%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
3.79%
G&A growth less than half of VET's 9.22%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.38%
Operating expenses growth 50-75% of VET's 7.58%. Bruce Berkowitz would examine efficiency.
6.39%
Total costs growth above 1.5x VET's 0.96%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-7.62%
Both companies reducing D&A. Martin Whitman would check industry patterns.
464.29%
EBITDA growth below 50% of VET's 8522.48%. Michael Burry would check for structural issues.
198.59%
EBITDA margin growth exceeding 1.5x VET's 16.39%. David Dodd would verify competitive advantages.
23983.33%
Operating income growth exceeding 1.5x VET's 141.84%. David Dodd would verify competitive advantages.
12803.59%
Operating margin growth exceeding 1.5x VET's 72.71%. David Dodd would verify competitive advantages.
18.18%
Other expenses growth less than half of VET's 101.36%. David Dodd would verify if advantage is sustainable.
2046.48%
Pre-tax income growth exceeding 1.5x VET's 295.17%. David Dodd would verify competitive advantages.
1142.90%
Pre-tax margin growth exceeding 1.5x VET's 239.38%. David Dodd would verify competitive advantages.
-300.00%
Tax expense reduction while VET shows 193.30% growth. Joel Greenblatt would examine advantage.
2022.22%
Net income growth exceeding 1.5x VET's 334.21%. David Dodd would verify competitive advantages.
1129.91%
Net margin growth exceeding 1.5x VET's 267.26%. David Dodd would verify competitive advantages.
1992.86%
EPS growth exceeding 1.5x VET's 334.07%. David Dodd would verify competitive advantages.
1992.86%
Diluted EPS growth exceeding 1.5x VET's 334.07%. David Dodd would verify competitive advantages.
0.92%
Share count reduction below 50% of VET's 0.17%. Michael Burry would check for concerns.
No Data
No Data available this quarter, please select a different quarter.